Francis Medical, Inc., an early stage company pioneering urological cancer treatments, beginning with prostate cancer, announced today that Coloplast has completed a $4 million equity investment in the company.

Founded in 2018, Francis Medical is a privately held company committed to developing urological cancer treatments that are tough on cancer and gentle on patients, with a compassionate belief that cancer tissue can be treated with minimally invasive treatments. The foundation of the company is a tribute to and legacy of the inventor's father, Francis Hoey, whose life was ended by prostate cancer with treatments that had harsh implications on his normal daily living. The platform technology utilizes water vapor energy to ablate targeted cancerous tissue while preserving surrounding structures, potentially minimizing the side effects often experienced with other cancer treatments. The company also has efforts underway in the areas of bladder and kidney cancer.